Menu
BOSTON and LAUSANNE, Switzerland, Aug. 04, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, announced today it will host its first-ever Investor Day on Tuesday, September 20, 2022, at PUBLIC Hotel in New York City. The event will begin at 1:30 p.m. EDT and is expected to conclude at approximately 5:30 p.m. EDT.
The event will feature presentations from the CEO and Co-Founder, Dr. Jurgi Camblong as well as from other members of the executive leadership team, followed by a Q&A session and reception.
Due to limited capacity, advanced registration is required for in-person attendance and is available by invitation. For more information, interested parties may contact Investor Relations at [email protected].
Additionally, the event will be webcast live and all interested parties are invited to access the webcast from the Investor Relations section of the company’s website. A replay of the webcast and slides shown during the presentations will also be available on the company’s website the following day.
A Media Snippet accompanying this announcement is available by clicking on the image or link below:
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn and Instagram. Where others see data, we see answers
Investor Contact:
Jennifer Pottage
Head of Investor Relations
[email protected]
Media Contact:
Kelly Katapodis
Senior Manager, Media & Communications
[email protected]
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
